Dapagliflozin improves erectile dysfunction in patients with type 2 diabetes mellitus: An open‐label, non‐randomized pilot study
Authors' conclusion
Dapagliflozin improves ED in patients with T2DM and enhances the efficacy of tadalafil. Further studies are needed to confirm our results explain the mechanism(s) by which dapagliflozin exerts its effects on ED.
Study context
- Population
- Caucasian men with T2DM and severe erectile dysfunction (ED)equally divided into 3 groups
- Participants
- 30 men
- Comparison
- Tadalafil vs tadalafil plus dapagliflozin vs dapagliflozin
- Primary endpoint
- Presence and severity of ED by IIEF-5 questionnaire and dynamic penile echo colour Doppler US (PCDU)
- Follow-up
- 3 months
Methodological detailsopen-label, non-randomized
- Open-label
- Non-randomized
Primary result
As reported in the abstract
IIEF-5 score improvement · end of treatment (3 months)
Significant improvement in IIEF-5 score in all three groups; in Groups 1, 2 and 3, respectively
294%, 375% and 197%
Further findings
- PCDU acceleration time change · end of treatment — Group 2
- −26.2%
PCDU peak systolic velocity increase · end of treatment
- Significant increase in peak systolic velocity by 178.9%, 339% and 153%
PCDU acceleration time change · end of treatment
- Significantly shortened in Group 2 and significantly lower than in Groups 1 and 3 (−7.2% and −6.6%)
PCDU end-diastolic velocity · end of treatment
- No significant difference after treatment
All end points
- Greatest rates of improvement in Group 2 for all end points
Original publication
Dapagliflozin improves erectile dysfunction in patients with type 2 diabetes mellitus: An open‐label, non‐randomized pilot study. Diabet Med. Published 15 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →